ABC of Mens Health Blog

Sepracor Inc. (Nasdaq: SEPR) announced the publication of a study of LUNESTA tablets in patients with insomnia and co-morbid generalized anxiety disorder (GAD) in the May issue of the Archives of General Psychiatry. This 595-patient study examined the safety and efficacy of LUNESTA co-administered with escitalopram oxalate, which is commonly used in the treatment of anxiety, versus co-administration of escitalopram and placebo in patients with insomnia and co-existing GAD. The study also evaluated the potential for co-administration of LUNESTA to increase the magnitude and/or accelerate the anxiolytic response versus escitalopram alone.
"Patients suffering from insomnia may have co-existing medical and psychiatric illnesses," said Mark H.N. Corrigan, M.D., Executive Vice President, Research and Development at Sepracor. "In fact, studies indicate that approximately ten percent of the adult population suffers from chronic insomnia, and that in approximately 80 percent of these patients, insomnia co-exists with other psychiatric and medical illnesses. The results of this study are consistent with results of other studies of LUNESTA evaluating insomnia with major depressive disorder and symptoms associated with perimenopause, which have shown that improvements in sleep can have positive effects on the co-morbid condition."
"To my knowledge, this is the first large-scale, double-blind, randomized clinical trial published that assessed the use of an insomnia treatment in conjunction with a selective serotonin reuptake inhibitor, or SSRI, in the treatment of patients with insomnia and co-morbid GAD," said W. generic ultram online buy Vaughn McCall, M.D., Professor and Chairman of the Department of Psychiatry and Behavioral Medicine at the Wake Forest University School of Medicine. "In this study, patients with insomnia and co-morbid GAD who took LUNESTA and escitalopram co-therapy showed improvements in measures of sleep and anxiety. Given the high incidence of insomnia symptoms co-existing with GAD, and the results seen in this clinical trial, I believe that further study of insomnia and its relationship to GAD is warranted."
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients 18 to 64 years of age who met DSM-IV-TR®1 criteria for insomnia and GAD were administered 10 mg of escitalopram nightly, plus either placebo or LUNESTA 3 mg nightly for eight weeks. The eight weeks of double-blind treatment were followed by a two-week run-out period in which all patients were administered escitalopram and placebo to evaluate the potential for rebound insomnia and withdrawal effects associated with LUNESTA discontinuation.
Patients treated with LUNESTA and escitalopram co-therapy demonstrated significant (pBuy generic viagra | Generic cialis pills no prescription | generic propecia online buy

Socially successful children tend to have fewer symptoms of anxiety or depression, while children with problems such as anxiety and depression tend to have difficulties forming relationships and being accepted by friends. However, it is difficult to determine whether the anxiety and depression lead to the social problems, or vice versa. New research suggests that social problems are more likely to contribute to anxiety and depression than the reverse. Generico viagra pillole senza ricetta The research also shows that this is particularly likely during the transition from adolescence into young adulthood.
The study, conducted by researchers at the University of Vermont and the University of Minnesota, appears in the March/April 2008 issue of the journal Child Development.
Using data from Project Competence, which has followed a group of 205 individuals from middle childhood (ages 8 to 12) over 20 years into young adulthood, the researchers used detailed interviews with participants and reports from their parents, teachers, and classmates to create measures of so-called internalizing problems (anxiety, depressed mood, being withdrawn) and social competence (how well one functions in relation to other people, particularly with respect to getting along with others and forming close relationships). They then examined how these measures related to each other over time, taking into account the stability of each (in other words, that children who have social problems at the start of the study may continue to have them over time).
The researchers found that young people who had more internalizing problems (such as anxiety and depression) at the start of the study were more likely to have those problems in adolescence and young adulthood. Those who were socially competent at the start of the study were socially competent as they grew up. However, in addition to this evidence of continuity, the study found evidence of spillover effects, where social problems contributed to increasing internalizing symptoms over time.
Children who were less socially competent in childhood were more likely to have symptoms of anxious or depressed mood in adolescence. Similarly, young people who were less socially competent in adolescence were at greater risk for symptoms of anxiety and depression in young adulthood. The findings remained the same when the researchers took into account some other possible explanations, such as intellectual functioning, the quality of parenting, social class, and such problems as fighting, lying, and stealing. And the results were generally the same for both males and females.
"Overall, our research suggests that social competence, such as acceptance by peers and developing healthy relationships, is a key influence in the development of future internalizing problems such as anxiety and depressed mood, especially over the transition years from adolescence into young adulthood," explains Keith Burt, assistant professor of psychology at the University of Vermont and the study’s lead author. "These results suggest that although internalizing problems have some stability across time, there is also room for intervention and change. More specifically, youth at risk for internalizing problems might benefit from interventions focused on building healthy relationships with peers."
The study was funded, in part, by the National Science Foundation and the National Institute of Mental Health.
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Summarized from Child Development, Vol. 79, Issue 2, The Interplay of Social Competence and Psychopathology Over 20 Years: Testing Transactional and Cascade Models by Burt, KB (University of Vermont), Obradovi?¦, J, Long, JD, and Masten, AS (University of Minnesota). Copyright 2008 The Society for Research in Child Development, Inc. All rights reserved.
Source: Andrea Browning
Society for Research in Child Development
comprare generico cialis | Generico levitra pillole senza ricetta | comprare generico viagra soft

Men’s Health News
Australian researchers have discovered that a mutated version of the BRCA-2 gene known to lead to breast and ovarian cancer, is also a culprit in prostate cancer in men.
The researchers from the Australian and New Zealand consortium kConFab which investigates familial breast cancer, say they suspect that as many as 2,000 Australian men possibly have the gene mutation; prostate cancer is the most common cancer in men in developed countries.
The researchers say men from families where the women have high rates of breast cancer could have a four times higher risk of prostate cancer.
The scientists believe the confirmation of the link is a world first and the research will help target those men suitable for genetic testing.
The research at kConFab has been investigating families with multiple cases of breast and ovarian cancer for a decade and became aware that prostate cancer also appeared to be common in some of the families.
The families carried a mutation in the BRCA2 gene, passed from one generation to the next, and the researchers say it was this factor which prompted them to explore whether the prostate cancers were caused by the familial genetic fault.
acheter viagra soft comprimes The team discovered that a man with a genetic fault in BRCA2 has almost four times the risk of developing prostate cancer than men in the general population and the cancers were more aggressive.
The revelation could lead men from a family with multiple cases of breast or ovarian cancer, to assess their risk in much the same way women already do with breast and ovarian cancer.
Trials are apparently now underway to search for early detection biomarkers for men who carry the faulty genes.
The research is published in the journal Clinical Cancer Research.
acheter levitra comprimes | Generique cialis pilules bon marche | generique viagra soft en ligne acheter

Rexahn Pharmaceuticals, Inc. (Buy generic propecia AMEX:RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced that the Company has initiated a Phase II clinical trial for its lead clinical compound ZoraxelTM, for the treatment of Erectile Dysfunction (ED). ZoraxelTM is being developed as an orally administered, on-demand-use tablet.
Zoraxel™ Phase II trial is a double-blind, placebo-controlled study. This multi-center trial is expected to be complete by the end of 2008.
Commenting on today’s news, Dr. Chang H. Ahn, Chairman and Chief Executive Officer of Rexahn, noted, "We are very pleased to announce the initiation of another Phase II trial. ZoraxelTM will prove itself a more effective, less toxic therapy for patients with erectile dysfunction."
About ZoraxelTM
ZoraxelTM is being developed as an immediate release tablet and has a well-established and excellent safety profile, different from current market leading PDE-5 inhibitors with many side effects (priapism, severe hypotension, myocardial infarction, sudden death, increased intraocular pressure and sudden hearing loss). Zoraxel™ is a dual neurotransmitter enhancer in the brain, and thus, acts through the central nervous system that regulates sexual functions, whereas the PDE-5 inhibitors work in the peripheral blood vessels and affect only erectile function. In the model studies, ZoraxelTM has been shown to significantly improve all three functions of sexual activity, i.e. sexual arousal, erection, and release. As such, ZoraxelTM may be a more effective ED treatment for patients who are both responsive and unresponsive to PDE-5 inhibitors.
About Erectile Dysfunction (ED)
ED is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. It is estimated to affect up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction. Clinical management of ED has progressed substantially in recent years. The advancement of phosphodiesterase-5 (PDE-5) inhibitor therapeutics quickly followed the scientific understanding of the nitric oxide (NO) signaling mechanism in erectile tissue. Adverse events affecting the vascular system have been a major concern with drugs that regulate that response. Investigations into the neurotransmission involved in penile erection, hormone actions involved in this response, and biochemical signal transduction processes within the erectile tissue, are indicative of significant areas of scientific pursuit.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life. For Additional information about Rexahn visit
Safe Harbor
This press release contains statements (including projections and business trends) that are forward-looking statements. Rexahn’s actual results may differ materially from the anticipated results and expectations expressed in these forward-looking statements as a result of certain risks and uncertainties, including, Rexahn’s lack of profitability, its auditor’s going concern qualification and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn’s development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn’s product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn’s claims; demand for and market acceptance of Rexahn’s drug candidates; Rexahn’s reliance on third party researchers and manufacturers to develop its product candidates; Rexahn’s ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date hereof; Rexahn assumes no obligation to update these forward-looking statements.
Rexahn Pharmaceuticals, Inc.
Buy generic soma | Buy lasix pills | generic diflucan online buy

Latest News For This Category
Some HIV-Positive People In Zambia Stopping Antiretroviral Treatment For Alternative Drugs, Health Official Says
22 Apr 2008
In Belgium, Euthanasia And Palliative Care Work Together
18 Apr 2008
Acupuncture Relieves Hot Flushes In Breast Cancer Patients Taking Tamoxifen
18 Apr 2008
View more news…
Latest Videos for Complementary Medicine
Yoga
Have you ever peeked into a room at your gym and seen people stretching, breathing deeply or just sitting in silence? kaufen viagra Ohne Rezept They were probably doing yoga, an ancient practice of body work and meditation. Our panel of experts will provide an overview of yoga, addressing the different forms of yoga and…
Tai Chi
Tai Chi was initially developed in China in the 14th century as a martial art of self-defense. But as it evolved, it came to be seen as an exercise promoting harmony, balance and relaxation of the body and mind. What is Tai Chi, and what can it do for you? Join our panel of experts for a discussion…
View more videos…
Advertisements
Add Your Advertisement Here
Most Read Articles From The Last 7 Days
Vitamin Supplements Don’t Help You Live Longer, Study
16 Apr 2008
Life Expectancy Disparities Increasing In The US
22 Apr 2008
Diet Designed To Lower Blood Pressure May Also Fight Heart Disease And Stroke
16 Apr 2008
Polycarbonate Baby Bottles Containing Bisphenol A May Become Banned In Canada
19 Apr 2008
Baby’s Gender Linked To Mother’s Diet At Conception
23 Apr 2008
Most Popular Categories
public health
neurology
nutrition
cancer
cardiovascular
hiv
diabetes
dermatology
obesity
alcohol
psychology
women’s health
infectious diseases
pediatrics
breast cancer
urology
pregnancy
gastrointestinal
pain
respiratory
prostate
bones
depression
smoking
medical devices
health insurance
medicare
hypertension
stem cell research
biology
alzheimer’s
sexual health
sleep
abortion
genetics
allergy
autism
eye health
adhd
it
multiple sclerosis
sports medicine
pharma industry
dentistry
liver disease
anxiety
arthritis
seniors
cholesterol
mrsa
kaufen levitra Ohne Rezept | Kaufen viagra soft pillen mastercard | generishe cialis online kaufen mastercard